SKF83822 hydrobromide 

SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates G_s/_olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors^[1].

SKF83822 (1 μM) increases DARPP-32 phosphorylation in Neostriatal slices. Treatment with SKF83822 for 5 min stimulates DARPP-32 Thr34 phosphorylation maximally at a concentration of 100 μM with a half maximal effect at ∼1 μM. SKF83822 (1 μM) does not affect the phosphorylation of DARPP-32 at Thr75, Ser97 or Ser130^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SKF83822 activates dopamine D1 receptors coupled to Gαs/olf and downstream cyclase activity. SKF83822 produces a locomotor response in both rodent and non-human primate models without affecting stereotypy, intense grooming, or dyskinesia. An acute injection of SKF83822 (0.4 mg/kg; i.p.) induced a greater than threefold increase in locomotor activity relative to the baseline period for each genotype^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

424.76

C₂₀H₂₃BrClNO₂

74115-10-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mahomi Kuroiwa, et al. Regulation of DARPP-32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J Neurochem. 2008 Nov;107(4):1014-26.  [Content Brief]

  [2]. Aliya L Frederick, et al. Neurobehavioral phenotyping of G(αq) knockout mice reveals impairments in motor functions and spatial working memory without changes in anxiety or behavioral despair. Front Behav Neurosci. 2012 Jun 19;6:29.  [Content Brief]